JP2024519170A5 - - Google Patents
Info
- Publication number
- JP2024519170A5 JP2024519170A5 JP2023573109A JP2023573109A JP2024519170A5 JP 2024519170 A5 JP2024519170 A5 JP 2024519170A5 JP 2023573109 A JP2023573109 A JP 2023573109A JP 2023573109 A JP2023573109 A JP 2023573109A JP 2024519170 A5 JP2024519170 A5 JP 2024519170A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- substituted
- alkyl
- optionally
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2107637.7 | 2021-05-28 | ||
| GBGB2107637.7A GB202107637D0 (en) | 2021-05-28 | 2021-05-28 | Compounds |
| GB2118635.8 | 2021-12-21 | ||
| GB202118635 | 2021-12-21 | ||
| PCT/GB2022/051367 WO2022248885A2 (en) | 2021-05-28 | 2022-05-27 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519170A JP2024519170A (ja) | 2024-05-08 |
| JP2024519170A5 true JP2024519170A5 (https=) | 2025-06-04 |
Family
ID=82019773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573109A Pending JP2024519170A (ja) | 2021-05-28 | 2022-05-27 | 化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240279241A1 (https=) |
| EP (1) | EP4347589A2 (https=) |
| JP (1) | JP2024519170A (https=) |
| KR (1) | KR20240013776A (https=) |
| AU (1) | AU2022279653A1 (https=) |
| BR (1) | BR112023024906A2 (https=) |
| CA (1) | CA3216294A1 (https=) |
| IL (1) | IL308438A (https=) |
| MX (1) | MX2023014138A (https=) |
| WO (1) | WO2022248885A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021247859A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Pyridopyrimidines and methods of their use |
| WO2023018812A1 (en) * | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| UY39906A (es) * | 2021-08-18 | 2023-03-31 | Jacobio Pharmaceuticals Co Ltd | Derivados de 1,4-oxazepano y usos de los mismos |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| IL312381A (en) | 2021-11-05 | 2024-06-01 | Frontier Medicines Corp | KRAS G12C inhibitors |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| EP4444289A4 (en) * | 2021-12-08 | 2025-12-17 | Kineta Inc | PYRIDOPYRIMIDINS AND METHODS FOR THEIR USE |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| JP2025510656A (ja) * | 2022-03-24 | 2025-04-15 | ベイジーン スウィッツァーランド ゲーエムベーハー | 複素環式化合物、その組成物、及びそれらを用いた治療方法 |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2023246777A1 (en) * | 2022-06-20 | 2023-12-28 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024012519A1 (zh) * | 2022-07-13 | 2024-01-18 | 北京华森英诺生物科技有限公司 | Pan-kras抑制剂 |
| WO2024041606A1 (zh) * | 2022-08-24 | 2024-02-29 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| CN120077051A (zh) * | 2022-10-21 | 2025-05-30 | 苏州亚盛药业有限公司 | Kras抑制剂 |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| WO2024119277A1 (en) * | 2022-12-08 | 2024-06-13 | Risen (Suzhou) Pharma Tech Co., Ltd. | Kras inhibitors and pharmaceutical uses thereof |
| CN120344526A (zh) * | 2022-12-14 | 2025-07-18 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| WO2024138206A1 (en) * | 2022-12-23 | 2024-06-27 | Frontier Medicines Corporation | Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof |
| PE20252775A1 (es) * | 2023-04-05 | 2025-12-22 | Pfizer | Compuestos de pirido[4,3-d]pirimidina |
| EP4709729A1 (en) | 2023-05-12 | 2026-03-18 | Jazz Pharmaceuticals Ireland Ltd. | Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant kras useful for the treatment of cancer |
| CN119101070A (zh) * | 2023-06-07 | 2024-12-10 | 上海璎黎药业有限公司 | 一种含氮杂环化合物、其药物组合物及应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025163494A1 (en) | 2024-01-29 | 2025-08-07 | Jazz Pharmaceuticals Ireland Ltd. | Condensed azines for the treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025235740A1 (en) * | 2024-05-08 | 2025-11-13 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| EP4192585A4 (en) * | 2020-08-04 | 2024-08-21 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4204412A4 (en) * | 2020-08-26 | 2024-10-09 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| WO2022256459A1 (en) * | 2021-06-01 | 2022-12-08 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
-
2022
- 2022-05-27 BR BR112023024906A patent/BR112023024906A2/pt unknown
- 2022-05-27 US US18/562,608 patent/US20240279241A1/en active Pending
- 2022-05-27 AU AU2022279653A patent/AU2022279653A1/en active Pending
- 2022-05-27 MX MX2023014138A patent/MX2023014138A/es unknown
- 2022-05-27 KR KR1020237044372A patent/KR20240013776A/ko active Pending
- 2022-05-27 EP EP22729759.5A patent/EP4347589A2/en active Pending
- 2022-05-27 IL IL308438A patent/IL308438A/en unknown
- 2022-05-27 JP JP2023573109A patent/JP2024519170A/ja active Pending
- 2022-05-27 CA CA3216294A patent/CA3216294A1/en active Pending
- 2022-05-27 WO PCT/GB2022/051367 patent/WO2022248885A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519170A5 (https=) | ||
| JP2024520791A5 (https=) | ||
| JOP20250111A1 (ar) | مثبطات kras كبيرة الحلقة وطرق استخدامها | |
| JP2024512767A5 (https=) | ||
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| JP2025508702A5 (https=) | ||
| MX2024010043A (es) | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas kras mutantes. | |
| JP2020521740A5 (https=) | ||
| CY1111093T1 (el) | 2,4,δι(ετερο-)αρυλαμινο(-οξυ)-5-υποκατεστημενες πυριμιδινες ως μεσα κατα των νεοπλασιων | |
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| CY1112086T1 (el) | Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| JP2008528467A5 (https=) | ||
| CA2386515A1 (en) | Piperazine derivatives | |
| JP2017528498A5 (https=) | ||
| JP2017504611A (ja) | 組合せ医薬 | |
| RU2003125887A (ru) | 6-замещенные пиридопиримидины | |
| JP2008528469A5 (https=) | ||
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| RU2007137651A (ru) | Иммунодепрессант и противоопухолевое средство, содержащее гетероциклическое соединение в качестве активного ингредиента | |
| JP2020510693A5 (https=) | ||
| US20230233557A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| JP2021529807A5 (https=) |